Pfizer Inc. logo

Pfizer Inc. (PFE)

Market Closed
26 Jun, 20:00
NYSE NYSE
$
24. 29
+0.62
+2.6193%
$
138.41B Market Cap
14.55 P/E Ratio
0.68% Div Yield
59.91M Volume
1.43 Eps
$ 23.67
Previous Close
Add Transaction
Day Range
23.74 24.35
Year Range
23.11 28.75
Want to track PFE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
US FDA approves Pfizer's drug for rare bleeding disorder

US FDA approves Pfizer's drug for rare bleeding disorder

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.

Reuters | 1 year ago
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock

An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock

There may be changes coming to this company, if the activists get their way.

Fool | 1 year ago
Why Pfizer Stock Tumbled by Nearly 3% on Thursday

Why Pfizer Stock Tumbled by Nearly 3% on Thursday

The company's latest institutional shareholder has made some troubling allegations against it.

Fool | 1 year ago
Pfizer battles activist fund Starboard, which has a $1 billion stake in company

Pfizer battles activist fund Starboard, which has a $1 billion stake in company

CNBC Angelica Peebles joins 'Power Lunch' to report on Pfizer's activist battle.

Youtube | 1 year ago
Ex-Pfizer Execs Backed Its Leadership. An Activist Investor Says They Were 'Threatened'

Ex-Pfizer Execs Backed Its Leadership. An Activist Investor Says They Were 'Threatened'

Pfizer (PFE) shares lost ground Thursday after two former executives released a statement supporting the company's current management after activist investor Starboard Value this week took a $1 billion stake in the struggling drug maker and moved to make changes.

Investopedia | 1 year ago
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks | 1 year ago
Starboard seeks probe after former Pfizer execs pull support for its campaign

Starboard seeks probe after former Pfizer execs pull support for its campaign

Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior executives were forced to publicly declare support for CEO Albert Bourla, the hedge fund said on Thursday.

Reuters | 1 year ago
Pfizer Skids After Former Execs Flip On Activist Investor, Siding With CEO Albert Bourla

Pfizer Skids After Former Execs Flip On Activist Investor, Siding With CEO Albert Bourla

Pfizer stock skidded Thursday after former executives Ian Read and Frank D'Amelio sided with the drugmaker over activist investor Starboard.

Investors | 1 year ago
Pfizer threatened to sue renegade executives prior to activist schism, Starboard's Smith says

Pfizer threatened to sue renegade executives prior to activist schism, Starboard's Smith says

Activist Starboard Value accused Pfizer of threatening litigation against two renegade former executives that initially were supportive of the investor's turnaround campaign at the pharmaceutical giant. Starboard's Jeff Smith called on the company to assemble a special committee to investigate the matter, describing it as "flagrantly unethical.

Cnbc | 1 year ago
Pfizer's stock dips after two former execs say they won't support Starboard, offer backing for CEO Albert Bourla

Pfizer's stock dips after two former execs say they won't support Starboard, offer backing for CEO Albert Bourla

Pfizer Inc.'s stock dipped early Thursday, after two of its former executives said they would not support an effort by activist shareholder Starboard Value to orchestrate a turnaround.

Marketwatch | 1 year ago
Pfizer's cancer drug combo improves overall survival in late-stage study

Pfizer's cancer drug combo improves overall survival in late-stage study

Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate cancer in a late-stage study.

Reuters | 1 year ago
Loading...
Load More